TRAF2 multitasking in TNF receptor-induced signaling to NF-κB, MAP kinases and cell death

Biochemical Pharmacology

Volumn 116, Issue , 2016, Pages 1-10

  Borghi, Alice ^a,b   Verstrepen, Lynn ^a,b   Beyaert, Rudi ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Apoptosis; Necroptosis; NF B; TNF; TRAF2

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; PSMD2 PROTEIN, HUMAN; TNF PROTEIN, HUMAN; TNFRSF1A PROTEIN, HUMAN; TNFRSF1B PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

APOPTOSIS; CELL DEATH; HUMAN; NECROPTOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; UBIQUITINATION; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CHEMISTRY; METABOLISM; NECROSIS; PHOSPHORYLATION; PROTEIN DOMAIN; PROTEIN STABILITY;

ANIMALS; APOPTOSIS; HUMANS; MAP KINASE SIGNALING SYSTEM; MODELS, BIOLOGICAL; NECROSIS; NF-KAPPA B; PHOSPHORYLATION; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STABILITY; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SIGNAL TRANSDUCTION; TNF RECEPTOR-ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR-ALPHA; UBIQUITINATION;

EID: 84961837933     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2016.03.009     Document Type: Review

References (88)

1. [1] Bradley, J.R., TNF-mediated inflammatory disease. J. Pathol. 214 (2008), 149–160.
2. [2] Baud, V., Karin, M., Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol. 11 (2001), 372–377.
3. [3] MacEwan, D.J., TNF ligands and receptors–a matter of life and death. Br. J. Pharmacol. 135 (2002), 855–875.
4. [4] Moss, M.L., Jin, S.L., Becherer, J.D., Bickett, D.M., Burkhart, W., Chen, W.J., et al. Structural features and biochemical properties of TNF-alpha converting enzyme (TACE). J. Neuroimmunol. 72 (1997), 127–129.
5. [5] Grell, M., Douni, E., Wajant, H., Lohden, M., Clauss, M., Maxeiner, B., et al. The transmembrane form of tumor-necrosis-factor is the prime activating ligand of the 80 kDa tumor-necrosis-factor receptor. Cell 83 (1995), 793–802.
6. [6] Naude, P.J., den Boer, J.A., Luiten, P.G., Eisel, U.L., Tumor necrosis factor receptor cross-talk. FEBS J. 278 (2011), 888–898.
7. [7] Micheau, O., Tschopp, J., Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114 (2003), 181–190.
8. [8] Cabal-Hierro, L., Lazo, P.S., Signal transduction by tumor necrosis factor receptors. Cell. Signal., 24, 2012.
9. [9] Xie, P., TRAF molecules in cell signaling and in human diseases. J. Mol. Signaling, 8, 2013, 7.
10. [10] Chung, J.Y., Park, Y.C., Ye, H., Wu, H., All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. J. Cell Sci. 115 (2002), 679–688.
11. [11] Ceccarelli, A., Di Venere, A., Nicolai, E., De Luca, A., Minicozzi, V., Rosato, N., et al. TNFR-associated factor-2 (TRAF2): not only a trimer. Biochemistry 54 (2015), 6153–6161.
12. [12] Yang, X.D., Sun, S.C., Targeting signaling factors for degradation, an emerging mechanism for TRAF functions. Immunol. Rev. 266 (2015), 56–71.
13. [13] Hsu, H., Shu, H.-B., Pan, M.-G., Goeddel, D.V., TRADD–TRAF2 and TRADD–FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 84 (1996), 299–308.
14. [14] Hsu, H.L., Xiong, J., Goeddel, D.V., The TNF receptor 1-associated protein TRADD signals cell-death and NF-Kappa-B activation. Cell 81 (1995), 495–504.
15. [15] Hsu, H., Huang, J., Shu, H.B., Baichwal, V., Goeddel, D.V., TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 4 (1996), 387–396.
16. [16] Fotin-Mleczek, M., Henkler, F., Samel, D., Reichwein, M., Hausser, A., Parmryd, I., et al. Apoptotic crosstalk of TNF receptors: TNF-R2-induces depletion of TRAF2 and IAP proteins and accelerates TNF-R1-dependent activation of caspase-8. J. Cell Sci. 115 (2002), 2757–2770.
17. [17] Park, S.M., Yoon, J.B., Lee, T.H., Receptor interacting protein is ubiquitinated by cellular inhibitor of apoptosis proteins (c-IAP1 and c-IAP2) in vitro. FEBS Lett. 566 (2004), 151–156.
18. [18] Vince, J.E., Pantaki, D., Feltham, R., Mace, P.D., Cordier, S.M., Schmukle, A.C., et al. TRAF2 must bind to cellular inhibitors of apoptosis for tumor necrosis factor (tnf) to efficiently activate nf-{kappa}b and to prevent tnf-induced apoptosis. J. Biol. Chem. 284 (2009), 35906–35915.
19. [19] Haas, T.L., Emmerich, C.H., Gerlach, B., Schmukle, A.C., Cordier, S.M., Rieser, E., et al. Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. Mol. Cell, 36, 2009.
20. [20] Varfolomeev, E., Goncharov, T., Fedorova, A.V., Dynek, J.N., Zobel, K., Deshayes, K., et al. C-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. J. Biol. Chem. 283 (2008), 24295–24299.
21. [21] Brenner, D., Blaser, H., Mak, T.W., Regulation of tumour necrosis factor signalling: live or let die. Nat. Rev. Immunol. 15 (2015), 362–374.
22. [22] Bertrand, M.J., Milutinovic, S., Dickson, K.M., Ho, W.C., Boudreault, A., Durkin, J., et al. CIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol. Cell 30 (2008), 689–700.
23. [23] Habelhah, H., Takahashi, S., Cho, S.G., Kadoya, T., Watanabe, T., Ronai, Z., Ubiquitination and translocation of TRAF2 is required for activation of JNK but not of p38 or NF-kappaB. EMBO J. 23 (2004), 322–332.
24. [24] Shi, C.S., Kehrl, J.H., Tumor necrosis factor (TNF)-induced germinal center kinase-related (GCKR) and stress-activated protein kinase (SAPK) activation depends upon the E2/E3 complex Ubc13-Uev1A/TNF receptor-associated factor 2 (TRAF2). J. Biol. Chem. 278 (2003), 15429–15434.
25. [25] Vallabhapurapu, S., Matsuzawa, A., Zhang, W., Tseng, P.H., Keats, J.J., Wang, H., et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat. Immunol. 9 (2008), 1364–1370.
26. [26] Lee, T.H., Shank, J., Cusson, N., Kelliher, M.A., The kinase activity of Rip1 is not required for tumor necrosis factor-alpha-induced IkappaB kinase or p38 MAP kinase activation or for the ubiquitination of Rip1 by Traf2. J. Biol. Chem. 279 (2004), 33185–33191.
27. [27] Legler, D.F., Micheau, O., Doucey, M.A., Tschopp, J., Bron, C., Recruitment of TNF receptor 1 to lipid rafts is essential for TNFalpha-mediated NF-kappaB activation. Immunity 18 (2003), 655–664.
28. [28] Zhang, L., Blackwell, K., Shi, Z., Habelhah, H., The RING domain of TRAF2 plays an essential role in the inhibition of TNFα-induced cell death but not in the activation of NF-κB. J. Mol. Biol. 396 (2010), 528–539.
29. [29] Yeh, W.C., Shahinian, A., Speiser, D., Kraunus, J., Billia, F., Wakeham, A., et al. Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. Immunity 7 (1997), 715–725.
30. [30] Tada, K., Okazaki, T., Sakon, S., Kobarai, T., Kurosawa, K., Yamaoka, S., et al. Critical roles of TRAF2 and TRAF5 in tumor necrosis factor-induced NF-κB activation and protection from cell death. J. Biol. Chem. 276 (2001), 36530–36534.
31. [31] Zhang, L., Blackwell, K., Thomas, G.S., Sun, S., Yeh, W.C., Habelhah, H., TRAF2 suppresses basal IKK activity in resting cells and TNFalpha can activate IKK in TRAF2 and TRAF5 double knockout cells. J. Mol. Biol. 389 (2009), 495–510.
32. [32] Zarnegar, B.J., Wang, Y., Mahoney, D.J., Dempsey, P.W., Cheung, H.H., He, J., et al. Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat. Immunol. 9 (2008), 1371–1378.
33. [33] Verstrepen, L., Beyaert, R., Receptor proximal kinases in NF-kappaB signaling as potential therapeutic targets in cancer and inflammation. Biochem. Pharmacol. 92 (2014), 519–529.
34. [34] Rodriguez, M., Cabal-Hierro, L., Carcedo, M.T., Iglesias, J.M., Artime, N., Darnay, B.G., et al. NF-kappaB signal triggering and termination by tumor necrosis factor receptor 2. J. Biol. Chem. 286 (2011), 22814–22824.
35. [35] Cabal-Hierro, L., Artime, N., Iglesias, J., Prado, M.A., Ugarte-Gil, L., Casado, P., et al. A TRAF2 binding independent region of TNFR2 is responsible for TRAF2 depletion and enhancement of cytotoxicity driven by TNFR1. Oncotarget 5 (2014), 224–236.
36. [36] Ji, W., Li, Y., Wan, T., Wang, J., Zhang, H., Chen, H., et al. Both internalization and AIP1 association are required for tumor necrosis factor receptor 2-mediated JNK signaling. Arterioscler. Thromb. Vasc. Biol. 32 (2012), 2271–2279.
37. [37] Cabal-Hierro, L., Rodriguez, M., Artime, N., Iglesias, J., Ugarte, L., Prado, M.A., et al. TRAF-mediated modulation of NF-kB AND JNK activation by TNFR2. Cell. Signal. 26 (2014), 2658–2666.
38. [38] Rothe, M., Wong, S.C., Henzel, W.J., Goeddel, D.V., A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 78 (1994), 681–692.
39. [39] He, L., Grammer, A.C., Wu, X., Lipsky, P.E., TRAF3 forms heterotrimers with TRAF2 and modulates its ability to mediate NF-{kappa}B activation. J. Biol. Chem. 279 (2004), 55855–55865.
40. [40] Zheng, C., Kabaleeswaran, V., Wang, Y., Cheng, G., Wu, H., Crystal structures of the TRAF2: cIAP2 and the TRAF1: TRAF2: cIAP2 complexes: affinity, specificity, and regulation. Mol. Cell 38 (2010), 101–113.
41. [41] Rothe, M., Pan, M.G., Henzel, W.J., Ayres, T.M., Goeddel, D.V., The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 83 (1995), 1243–1252.
42. [42] Marchetti, L., Klein, M., Schlett, K., Pfizenmaier, K., Eisel, U.L.M., Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate-induced excitotoxicity is enhanced by N-methyl-D-aspartate receptor activation essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinase-dependent NF-κB pathway. J. Biol. Chem. 279 (2004), 32869–32881.
43. [43] Gustin, J.A., Ozes, O.N., Akca, H., Pincheira, R., Mayo, L.D., Li, Q., et al. Cell type-specific expression of the IkappaB kinases determines the significance of phosphatidylinositol 3-kinase/Akt signaling to NF-kappa B activation. J. Biol. Chem. 279 (2004), 1615–1620.
44. [44] Depuydt, B., van Loo, G., Vandenabeele, P., Declercq, W., Induction of apoptosis by TNF receptor 2 in a T-cell hybridoma is FADD dependent and blocked by caspase-8 inhibitors. J. Cell Sci. 118 (2005), 497–504.
45. [45] Aggarwal, B.B., Shishodia, S., Ashikawa, K., Bharti, A.C., The role of TNF and its family members in inflammation and cancer: lessons from gene deletion. Curr. Drug Targets Inflamm. Allergy 1 (2002), 327–341.
46. [46] Wicovsky, A., Henkler, F., Salzmann, S., Scheurich, P., Kneitz, C., Wajant, H., Tumor necrosis factor receptor-associated factor-1 enhances proinflammatory TNF receptor-2 signaling and modifies TNFR1-TNFR2 cooperation. Oncogene 28 (2009), 1769–1781.
47. [47] Ruspi, G., Schmidt, E.M., McCann, F., Feldmann, M., Williams, R.O., Stoop, A.A., et al. TNFR2 increases the sensitivity of ligand-induced activation of the p38 MAPK and NF-kappaB pathways and signals TRAF2 protein degradation in macrophages. Cell. Signal. 26 (2014), 683–690.
48. [48] Li, X., Yang, Y., Ashwell, J.D., TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2. Nature 416 (2002), 345–347.
49. [49] Rauert, H., Wicovsky, A., Muller, N., Siegmund, D., Spindler, V., Waschke, J., et al. Membrane tumor necrosis factor (TNF) induces p100 processing via TNF receptor-2 (TNFR2). J. Biol. Chem. 285 (2010), 7394–7404.
50. [50] Sun, S.C., The noncanonical NF-kappaB pathway. Immunol. Rev. 246 (2012), 125–140.
51. [51] Schneider-Brachert, W., Tchikov, V., Neumeyer, J., Jakob, M., Winoto-Morbach, S., Held-Feindt, J., et al. Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles. Immunity 21 (2004), 415–428.
52. [52] Wang, L., Du, F., Wang, X., TNF-alpha induces two distinct caspase-8 activation pathways. Cell 133 (2008), 693–703.
53. [53] Tenev, T., Bianchi, K., Darding, M., Broemer, M., Langlais, C., Wallberg, F., et al. The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol. Cell 43 (2011), 432–448.
54. [54] Nguyen, L.T., Duncan, G.S., Mirtsos, C., Ng, M., Speiser, D.E., Shahinian, A., et al. TRAF2 deficiency results in hyperactivity of certain TNFR1 signals and impairment of CD40-mediated responses. Immunity 11 (1999), 379–389.
55. [55] Piao, J.-H., Hasegawa, M., Heissig, B., Hattori, K., Takeda, K., Iwakura, Y., et al. Tumor necrosis factor receptor-associated factor (TRAF) 2 controls homeostasis of the colon to prevent spontaneous development of murine inflammatory bowel disease. J. Biol. Chem. 286 (2011), 17879–17888.
56. [56] Gentle, I.E., Wong, W.W., Evans, J.M., Bankovacki, A., Cook, W.D., Khan, N.R., et al. In TNF-stimulated cells, RIPK1 promotes cell survival by stabilizing TRAF2 and cIAP1, which limits induction of non-canonical NF-kappaB and activation of caspase-8. J. Biol. Chem. 286 (2011), 13282–13291.
57. [57] Gonzalvez, F., Lawrence, D., Yang, B., Yee, S., Pitti, R., Marsters, S., et al. TRAF2 sets a threshold for extrinsic apoptosis by tagging caspase-8 with a ubiquitin shutoff timer. Mol. Cell 48 (2012), 888–899.
58. [58] Galluzzi, L., Vitale, I., Abrams, J.M., Alnemri, E.S., Baehrecke, E.H., Blagosklonny, M.V., et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ. 19 (2012), 107–120.
59. [59] Holler, N., Zaru, R., Micheau, O., Thome, M., Attinger, A., Valitutti, S., et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat. Immunol. 1 (2000), 489–495.
60. [60] He, S., Wang, L., Miao, L., Wang, T., Du, F., Zhao, L., et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell 137 (2009), 1100–1111.
61. [61] Cho, Y.S., Challa, S., Moquin, D., Genga, R., Ray, T.D., Guildford, M., et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 137 (2009), 1112–1123.
62. [62] Zhao, J., Jitkaew, S., Cai, Z., Choksi, S., Li, Q., Luo, J., et al. Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis. Proc. Natl. Acad. Sci. U.S.A. 109 (2012), 5322–5327.
63. [63] Sun, L., Wang, H., Wang, Z., He, S., Chen, S., Liao, D., et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 148 (2012), 213–227.
64. [64] Wang, H., Sun, L., Su, L., Rizo, J., Liu, L., Wang, L.-F., et al. Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. Mol. Cell 54 (2014), 133–146.
65. [65] Petersen, S.L., Chen, T.T., Lawrence, D.A., Marsters, S.A., Gonzalvez, F., Ashkenazi, A., TRAF2 is a biologically important necroptosis suppressor. Cell Death Differ. 22 (2015), 1846–1857.
66. [66] Carpentier, I., Beyaert, R., TRAF1 is a TNF inducible regulator of NF-kappaB activation. FEBS Lett. 460 (1999), 246–250.
67. [67] Wu, C.J., Conze, D.B., Li, X., Ying, S.X., Hanover, J.A., Ashwell, J.D., TNF-alpha induced c-IAP1/TRAF2 complex translocation to a Ubc6-containing compartment and TRAF2 ubiquitination. EMBO J. 24 (2005), 1886–1898.
68. [68] Kovalenko, A., Chable-Bessia, C., Cantarella, G., Israel, A., Wallach, D., Courtois, G., The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 424 (2003), 801–805.
69. [69] Li, L., Soetandyo, N., Wang, Q., Ye, Y., The zinc finger protein A20 targets TRAF2 to the lysosomes for degradation. Biochim. Biophys. Acta 1793 (2009), 346–353.
70. [70] Catrysse, L., Vereecke, L., Beyaert, R., van Loo, G., A20 in inflammation and autoimmunity. Trends Immunol. 35 (2014), 22–31.
71. [71] Yamaguchi, N., Oyama, M., Kozuka-Hata, H., Inoue, J., Involvement of A20 in the molecular switch that activates the non-canonical NF-small ka, CyrillicB pathway. Sci. Rep., 3, 2013, 2568.
72. [72] Li, S., Wang, L., Dorf, M.E., PKC phosphorylation of TRAF2 mediates IKKα/β recruitment and K63-linked polyubiquitination. Mol. Cell, 33, 2008.
73. [73] Blackwell, K., Zhang, L., Thomas, G.S., Sun, S., Nakano, H., Habelhah, H., TRAF2 phosphorylation modulates tumor necrosis factor alpha-induced gene expression and cell resistance to apoptosis. Mol. Cell. Biol. 29 (2009), 303–314.
74. [74] Thomas, G.S., Zhang, L., Blackwell, K., Habelhah, H., Phosphorylation of TRAF2 within its RING domain inhibits stress-induced cell death by promoting IKK and suppressing JNK activation. Cancer Res. 69 (2009), 3665–3672.
75. [75] Zhang, L., Blackwell, K., Altaeva, A., Shi, Z., Habelhah, H., TRAF2 phosphorylation promotes NF-kappaB-dependent gene expression and inhibits oxidative stress-induced cell death. Mol. Biol. Cell 22 (2011), 128–140.
76. [76] Pereira, R., Lago, P., Faria, R., Torres, T., Safety of anti-TNF therapies in immune-mediated inflammatory diseases: focus on infections and malignancy. Drug Dev. Res. 76 (2015), 419–427.
77. [77] Apostolaki, M., Armaka, M., Victoratos, P., Kollias, G., Cellular mechanisms of TNF function in models of inflammation and autoimmunity. Curr. Dir. Autoimmun. 11 (2010), 1–26.
78. [78] Vereecke, L., Sze, M., Mc Guire, C., Rogiers, B., Chu, Y., Schmidt-Supprian, M., et al. Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor-induced toxicity and experimental colitis. J. Exp. Med. 207 (2010), 1513–1523.
79. [79] Reuss, R., Mirau, A., Mistarz, M., Kraus, J., Bodeker, R.H., Oschmann, P., TRAF2 is upregulated in relapsing-remitting multiple sclerosis. Neuroimmunomodulation 20 (2013), 177–183.
80. [80] Benetatos, C.A., Mitsuuchi, Y., Burns, J.M., Neiman, E.M., Condon, S.M., Yu, G., et al. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models. Mol. Cancer Ther. 13 (2014), 867–879.
81. [81] Döppler, H., Liou, G.-Y., Storz, P., Downregulation of TRAF2 mediates NIK-induced pancreatic cancer cell proliferation and tumorigenicity. PLoS One, 8, 2013.
82. [82] Fulda, S., Promises and challenges of Smac mimetics as cancer therapeutics. Clin. Cancer Res. 21 (2015), 5030–5036.
83. [83] Jia, L., Sun, Y., SCF E3 ubiquitin ligases as anticancer targets. Curr. Cancer Drug Targets 11 (2011), 347–356.
84. [84] Manna, S.K., Babajan, B., Raghavendra, P.B., Raviprakash, N., Sureshkumar, C., Inhibiting TRAF2-mediated activation of NF-kappaB facilitates induction of AP-1. J. Biol. Chem. 285 (2010), 11617–11627.
85. [85] Liu, Y., Zhang, D., Duan, C., Jia, L., Xie, P., Zheng, D., et al. Studies on pharmacokinetics and tissue distribution of bifendate nanosuspensions for intravenous delivery. J. Microencapsul. 29 (2012), 194–203.
86. [86] Aggarwal, B.B., Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 3 (2003), 745–756.
87. [87] Grech, A.P., Amesbury, M., Chan, T., Gardam, S., Basten, A., Brink, R., TRAF2 differentially regulates the canonical and noncanonical pathways of NF-kappaB activation in mature B cells. Immunity 21 (2004), 629–642.
88. [88] Etemadi, N., Chopin, M., Anderton, H., Tanzer, M.C., Rickard, J.A., Abeysekra, W., TRAF2 regulates TNF and NF-kappaB signalling to suppress apoptosis and skin inflammation independently of Sphingosine kinase-1.eLife., 4, 2015.